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Background: Maintaining high treatment adherence levels is critical for effective management of chronic
diseases. The Adherence Starts with Knowledge 20 (ASK-20) questionnaire is the only linguistically
validated patient-reported treatment adherence tool available in Japan. We conducted additional ana-
lyses on ASK-20 data from Japanese adults with asthma.
Methods: This was a prospective, non-interventional, single-visit, multi-centre study in Japanese adults
(n ¼ 300) with asthma receiving long-term treatment with inhaled corticosteroids (ICS) or ICS/long-
acting beta-agonists. We tested the reliability, validity and the relationship between different adher-
ence conditions and ASK-20 score. At one centre, ICS adherence prescription rate was calculated
retrospectively based on 2-year percentage ICS adherence data contained within medical records.
Results: The ASK-20 had good internal consistency reliability (Cronbach's alpha ¼ 0.76; n ¼ 290).
Discriminant validity was demonstrated with signiﬁcant correlations between the percentage ICS
adherence rates and both the mean ASK-20 total score and mean total barrier count (TBC) (r ¼ 0.51
and 0.58, p < 0.001; n ¼ 111). The ASK-20 total score discriminated between subjects with good and
poor adherence measured by patients' reported questionnaire and between those of high and low
percentage ICS adherence rates. All other factors that possibly affect adherence were correlated with the
mean ASK-20 total score and mean TBC in addition to the number of medicines taken every day.
Conclusions: The Japanese ASK-20 is a reliable tool for assessing possible medication adherence barriers
and adherence behaviour in Japanese adults with asthma. Furthermore, our results are comparable with
those obtained using the ASK-20 in the United States.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Maintaining high levels of treatment adherence is critical for the
effective management of chronic diseases.1 Medication compliance
in asthma is lower than for other chronic illnesses2 with less than
40% of patients taking their medication as prescribed.3 In a study by
Breekveldt-Postma et al., persistence rates (deﬁned as the number
of days from start to time of ﬁrst failure to continue renewal of they Medicine, Juntendo Tokyo
-ku, Tokyo 136-0075, Japan.
ety of Allergology.
rgology. Production and hosting by Else
t al., Assessing usability of th
ving inhaled corticosteroids linitial treatment) after one year were low for patients using inhaled
corticosteroid (ICS) treatment (10%) and ﬁxed combination ICS
(15%),4 which concurred with ﬁndings from an earlier pharmacy
database review.5 As such, symptoms in patients with asthma are
not well controlled6 and patients are more likely to have depressive
symptoms and a lower quality of life.7 Furthermore, non-adherence
contributes to an increased number of exacerbations.8
Patients may not take their medication as instructed for many
reasons: not fully understanding the role of their asthma treat-
ment; not receiving clear guidelines on how to use their medica-
tion9; or having concerns about their treatment and associated side
effects.10vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
e “Adherence Starts with Knowledge 20” (ASK-20) questionnaire for
ong term, Allergology International (2016), http://dx.doi.org/10.1016/
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lenging, partly because of the variety of chronic conditions.11
Variation in patients' conditions and their predisposition to hide
non-adherence add to the complexity of assessment.11 Patients
who underuse their maintenance therapies tend to over-estimate
the amount they take and those who overuse tend to underesti-
mate.12 Therefore, effective and economical tools are needed to
better evaluate and improve our understanding of the barriers to
treatment adherence. This, in turn, will improve communication
between doctors and their patients.
Generally, treatment adherence measures are either objective,
such as pill counts or the use of electronic monitoring devices, or
subjective, involving self-reporting by the patient or use of physi-
cian estimates.13,14 Adherence rates can change when different
methods of assessments are used. For example, objectively
measured adherence values (60.8%) were found to be signiﬁcantly
lower than those that had been self-reported (93.6%).15
Patient-reported adherence screening tools include the Morisky
Medication Adherence Scale (MMAS),16 the Medication Adherence
Rating Scale (MARS)17 and the Adherence Starts with Knowledge 20
(ASK-20) questionnaire.11,13 Currently, only the ASK-20 is available
in Japan.18
The ASK-20 was developed to identify and reduce the number of
barriers to treatment compliance to improve adherence. It has been
validated in the United States (US) and has improved our ability to
identify speciﬁc treatment adherence barriers comparedwith other
relevant patient-reporting tools.11,13 Furthermore, the ASK-20
signiﬁcantly reduces the number of adherence barriers (3.8e2.8,
p ¼ 0.0021) and improves control of asthma symptoms, deﬁned as
an Asthma Control Test (ACT) score >19 (50.0e64.6%; p¼ 0.0285).19
In the US, satisfactory validity, internal consistency and reliability
have also been seen with the ASK-20.11,13 We performed a study toTable 1
Demographic characteristics of the Per Protocol population (n ¼ 290) and the inhaled co
Item
Age (years) Overall
Mean (standard deviation)
Minimumemaximum
Age range, n (%) 20e34
35e49
50e64
65
Gender, n (%) Female
Male
Severity of asthma, n (%)y Mild
Moderate
Severe
Current medical history, n (%) Respiratory
COPD
Perennial allergic rhinitis
Seasonal allergic rhinitis
Other respiratory
Cardiovascular
Gastrointestinal
Renal
Central nervous system
Others
ACT total score, n (%) 19
20e24
25
Current use of ICS, n (%) ICS/LABA
Fluticasone propionate/salmet
Budesonide/formoterol
ICS alone
ACT, Asthma Control Test; COPD, chronic obstructive pulmonary disorder; ICS, inhaled c
y Severity was based on the evaluation criteria of the guideline, ‘Asthma Prevention a
z Previously published data added here for comparison.18
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validation data from this study have been published.18 In this
publication, we present outcomes from additional analyses of the
original data to test the validity and reliability of the ASK-20 and
investigate the impact of different adherence conditions.
Methods
Study design and population
This was a prospective, non-interventional, single-visit study
conducted at 3 centres in Japan between 31 January and 20
November 2013. Approvals were given by the ethical review board
at each institution: Juntendo University School of Medicine
Research Ethics Committee (approval number: 962); The Fraternity
Memorial Hospital Ethics Committee (113); and Toho University
Omori Medical Center Ethics Committee (24-240). Written
informed consent was obtained from each subject before they
underwent any study measures and anonymity was preserved us-
ing methods approved by the ethical review boards. Japanese men
and women aged 20 years or older were eligible if they had
received ICS or ICS/long-acting beta-agonist (LABA) at a ﬁxed dose
for 2 years but had not received two or more ICS or ICS/LABA and
had not visited other hospitals for bronchial asthma treatment.
Measures
At the consultation visit (baseline), subjects completed the
following self-reporting questionnaires: ASK-20; ACT, to assess
asthma symptoms; a questionnaire to assess the level of satisfac-
tion with asthma treatment; and a questionnaire to assess treat-
ment status in the previous 2 weeks. In addition, asthma severityrticosteroid adherence sub-group (n ¼ 111).
Number of subjects n (%)
PP populationz ICS sub-group
290 111
57.7 (16.16) 56.3 (13.92)
23e94 27e88
22 (7.6) 6 (5.4)
80 (27.6) 31 (27.9)
80 (27.6) 40 (36.0)
108 (37.2) 34 (30.6)
181 (62.4) 72 (64.9)
109 (37.6) 39 (35.1)
114 (39.3) 34 (30.6)
106 (36.6) 26 (23.4)
70 (24.1) 51 (45.9)
135 (46.6) 53 (47.7)
14 (4.8) 4 (3.6)
65 (22.4) 21 (18.9)
42 (14.5) 21 (18.9)
23 (7.9) 12 (10.8)
82 (28.3) 29 (26.1)
61 (21.0) 23 (20.7)
10 (3.4) 3 (2.7)
14 (4.8) 5 (4.5)
120 (41.4) 46 (41.4)
96 (33.1) 28 (25.2)
115 (39.7) 46 (41.4)
79 (27.2) 37 (33.3)
207 (71.4) 87 (78.4)
erol 131 (45.2) 61 (55.0)
76 (26.2) 26 (23.4)
83 (28.6) 24 (21.6)
orticosteroid; LABA, long-acting beta-agonist.
nd Management Guideline 2012, Japan.’20
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was collected. The outcomes of these assessments have been pre-
viously summarised.18 At 1 centre, the prescription rate of ICS
adherence was calculated retrospectively based on 2-year per-
centage ICS adherence data contained within medical records. The
study design, eligible population and measures have already been
reported.18
Statistical analysis
SAS statistical software version 9.2 was used for all analyses. Of
the 300 subjects planned for enrolment,18 120 were to be analysed
for ICS adherence to give an estimated accuracy of 3.3%e5.7%, based
on an assumption that the proportion of patients estimated to have
barriers to adherence is 10e50%.
The ‘per protocol’ (PP) analysis set (i.e. subjects who completed
the ASK-20 without signiﬁcant deviation from the protocol) was
used for the analyses described. The ceiling/ﬂoor effect tested
whether there was any bias in scores (i.e., 50% of ‘1’ or ‘5’ scores)
regardless of adherence condition. For each survey item, the ASK-
20 total score and ‘with barrier’ frequency, previously deﬁned by
Matza et al.,13 were analysed to compare differences between the
poor adherence group (i.e., subjects who missed a dose [poor-1]
and did not take medication as directed [poor-2]) and the good
adherence group (i.e., subjects who didn't miss a dose [good-1] and
took all medication as directed [good-2]).
Internal consistency reliability was assessed for the ASK-20 total
score and total barrier count (TBC) using Cronbach's coefﬁcient
alpha, with a value 0.70 considered acceptable.13,21e23 Discrimi-
nant validity was analysed by calculating the differences in the
ASK-20 total score and TBC 95% conﬁdence interval (CI) between
the good and poor adherence groups. Regression analysis deter-
mined the relationship between the ASK-20 total score or TBC and
factors that possibly affect adherence, including age, ACT score,
number of medicines taken daily (not including immunoglobulin-
E), number of missed doses in the previous 2 weeks, number of
days the subject didn't take the medication as directed in the
previous 2 weeks and subject satisfaction with current treatment.
Spearman's correlation conﬁrmed any relationship between the
ASK-20 total score or TBC and the prescription rate of ICS adherence
(n ¼ 111) where: rate ¼ [actual amount of drug prescribed in theTable 2
A summary of the bias analysis outcomes showing ﬂoor and ceiling effects in responses to
Question
1 I just forget to take my medicines some of the time.
2 I run out of my medicine because I don't get reﬁlls on time.
3 My use of alcohol gets in the way of taking my medicines.
4 I worry about how medicine will affect my sexual health.
5 I sometimes forget things that are important to me.
6 I have felt sad, down, or blue during the past month.
7 I feel conﬁdent that each one of my medicines will help me.
8 I know if I am reaching my health goals.
9 I have someone who I can call with questions about my medicines.
10 I understand my doctor's/nurse's instructions about the medicines I take.
11 My doctor/nurse and I work together to make decisions.
12 I am able to read and understand pill bottle labels.
13 Taking medicines more than once a day is inconvenient.
14 I have to take too many medicines a day.
15 It is hard for me to swallow the pills I have to take.
16 Taken a medicine more or less often than prescribed?
17 Skipped or stopped taking a medicine because you didn't think it was wor
18 Skipped or stopped taking medicine because it made you feel bad?
19 Skipped, stopped, not reﬁlled, or taken less medicine because of the cost?
20 Not had medicine with you when it was time to take it?
SD, standard deviation. We used the Japanese version of ASK-20 in this study.
Please cite this article in press as: Atsuta R, et al., Assessing usability of th
Japanese adults with bronchial asthma receiving inhaled corticosteroids l
j.alit.2016.09.001previous 2 years]/[theoretical amount of drug which should have
been prescribed in the same period]  100.
The 95% CI for the ASK-20 total score or TBC in the high pre-
scription ICS adherence rate group (>75 to 125%) was compared
with those of the low rate group (25 to 75%).Results
Demographic characteristics
Demographic characteristics of the ICS adherence sub-group
were similar to those of the PP population (Table 1)18 with a few
exceptions: the ICS sub-group had a higher proportion of subjects
with severe asthma, a lower proportion with moderate asthma,
more subjects had an ACT total score between 20 and 24 than in
either of the other score ranges, and the majority was taking ICS/
LABA.Descriptive ASK-20 outcomes and analysis of bias
For the ICS adherence sub-group, the mean ASK-20 total score
was 38.9 (95% CI: 36.98e40.74) and mean TBC was 3.5 (2.91e3.99)
which were similar to those of the PP population.18
In the PP population, our analysis of bias showed no ceiling ef-
fects, but ﬂoor effects were observed for 9 items (Q2, Q3, Q4, Q15,
Q16, Q17, Q18, Q19, Q20) meaning these items were rated with the
lowest possible score by over 50% of this sub-group (Table 2). The
comparison between the good and poor adherence sub-groups in
relation to the mean ASK-20 scores and ‘with barrier frequency’ for
each question is presented in Table 3. Similar scores were seen in
the Good-1 and Poor-1 adherence sub-groups with a difference of
less than 1 unit between the groups for the majority (90%) of ASK-
20 questions. However, there was a greater than 1 unit difference in
mean ASK-20 score between the Poor-1 and Good-1 sub-groups for
Q1 (“I just forget to take my medicines some of the time”) and Q16
(“Taken a medicine more or less often than prescribed?”), with the
higher score seen in the Poor-1 sub-group. In the Poor-1 sub-group,
a greater than 50% ‘with barrier frequency’ was seen for Q1 and
Q16; the highest frequency was reported for Q1 (76.5%). In the
Good-1 sub-group, all questions had less than a 50% ‘with barrierASK-20 questions in Japanese adults with asthma (Per Protocol population; n¼ 290).
Score
Mean (SD) Median Floor n (%) Ceiling n (%)
2.6 (1.42) 2.0 104 (35.9) 16 (5.5)
1.4 (0.81) 1.0 205 (70.7) 1 (0.3)
1.3 (0.74) 1.0 227 (78.3) 2 (0.7)
1.5 (0.94) 1.0 210 (72.4) 4 (1.4)
1.9 (1.12) 2.0 141 (48.6) 7 (2.4)
2.3 (1.36) 2.0 116 (40.0) 16 (5.5)
1.9 (0.95) 2.0 104 (35.9) 11 (3.8)
2.5 (0.97) 2.0 42 (14.5) 9 (3.1)
2.7 (1.32) 2.0 51 (17.6) 45 (15.5)
1.7 (0.69) 2.0 116 (40.0) 2 (0.7)
1.8 (0.81) 2.0 117 (40.3) 4 (1.4)
1.8 (0.74) 2.0 111 (38.3) 2 (0.7)
2.5 (1.36) 2.0 100 (34.5) 23 (7.9)
2.5 (1.35) 2.0 92 (31.7) 29 (10.0)
1.7 (0.95) 1.0 155 (53.4) 4 (1.4)
2.2 (1.55) 1.0 157 (54.1) 37 (12.8)
king? 1.3 (0.79) 1.0 241 (83.1) 6 (2.1)
1.3 (0.79) 1.0 242 (83.4) 5 (1.7)
1.1 (0.45) 1.0 270 (93.1) 2 (0.7)
1.9 (1.30) 1.0 175 (60.3) 19 (6.6)
e “Adherence Starts with Knowledge 20” (ASK-20) questionnaire for
ong term, Allergology International (2016), http://dx.doi.org/10.1016/
Table 3
The association between adherence and ‘with barrier frequency’ with the mean ASK-20 scores for each question in the ASK-20 (Per Protocol population; n ¼ 290).
Question Subjects with
adherence
barrier n (%)
Subjects without a missed dose Subjects who missed a dose Subjects who took medication
as directed
Those who did not take medication
as directed
Good-1y (n ¼ 205) Poor-1y (n ¼ 85) Good-2z (n ¼ 197) Poor-2z (n ¼ 93)
Mean
score
With barrier
n (%)
Mean
score
With barrier
n (%)
Mean
score
With barrier
n (%)
Mean
score
With barrier
n (%)
1 119 (41.0) 2.1 54 (26.3) 3.6 65 (76.5) 2.1 47 (23.9) 3.6 72 (77.4)
2 24 (8.3) 1.3 10 (4.9) 1.7 14 (16.5) 1.4 12 (6.1) 1.6 12 (12.9)
3 23 (7.9) 1.2 8 (3.9) 1.6 15 (17.6) 1.2 7 (3.6) 1.6 16 (17.2)
4 17 (5.9) 1.4 8 (3.9) 1.8 9 (10.6) 1.4 9 (4.6) 1.7 8 (8.6)
5 39 (13.4) 1.8 25 (12.2) 2.2 14 (16.5) 1.9 26 (13.2) 2.0 13 (14.0)
6 16 (5.5) 2.3 8 (3.9) 2.4 8 (9.4) 2.2 10 (5.1) 2.6 6 (6.5)
7 44 (15.2) 1.9 28 (13.7) 2.0 16 (18.8) 1.9 25 (12.7) 2.0 19 (20.4)
8 135 (46.6) 2.4 91 (44.4) 2.6 44 (51.8) 2.5 89 (45.2) 2.5 46 (49.5)
9 83 (28.6) 2.7 56 (27.3) 2.8 27 (31.8) 2.7 53 (26.9) 2.8 30 (32.3)
10 23 (7.9) 1.7 21 (10.2) 1.7 2 (2.4) 1.7 19 (9.6) 1.7 4 (4.3)
11 34 (11.7) 1.7 21 (10.2) 1.8 13 (15.3) 1.7 23 (11.7) 1.8 11 (11.8)
12 33 (11.4) 1.7 21 (10.2) 1.8 12 (14.1) 1.7 20 (10.2) 1.8 13 (14.0)
13 86 (29.7) 2.3 45 (22.0) 3.1 41 (48.2) 2.2 39 (19.8) 3.2 47 (50.5)
14 77 (26.6) 2.4 53 (25.9) 2.6 24 (28.3) 2.5 52 (26.4) 2.6 25 (26.9)
15 18 (6.2) 1.7 13 (6.3) 1.8 5 (5.9) 1.7 13 (6.6) 1.8 5 (5.4)
16 103 (35.5) 1.8 48 (23.4) 3.3 55 (64.7) 1.7 41 (20.8) 3.4 62 (66.7)
17 16 (5.5) 1.2 6 (2.9) 1.5 10 (11.8) 1.1 3 (1.5) 1.7 13 (14.0)
18 19 (6.6) 1.2 11 (5.4) 1.4 8 (9.4) 1.2 10 (5.1) 1.5 9 (9.7)
19 6 (2.1). 1.1 2 (1.0) 1.2 4 (4.7) 1.0 1 (0.5) 1.2 5 (5.4)
20 49 (16.9) 1.6 20 (9.8) 2.5 29 (34.1) 1.6 16 (8.1) 2.5 33 (35.5)
y ‘Good-1’ was deﬁned as the good adherence group that responded ‘No’ to the question, ‘Have you missed doses of any of your medicines in the last 2 weeks?’; Poor-1 was
deﬁned as the poor adherence group who responded ‘Yes’ to the same question. Questions were from the treatment adherence questionnaire.
z ‘Good-2’ was deﬁned as the good adherence group that responded ‘No’ to the question, were there any days that you did not take your medicine exactly as directed in the
last 2 weeks?’; Poor-2 was deﬁned as the poor adherence group who responded ‘Yes’ to the same question. Questions were from the treatment adherence questionnaire.
R. Atsuta et al. / Allergology International xxx (2016) 1e74frequency’. A similar outcomewas seenwhen comparing the Good-
2 and Poor-2 sub-groups.
Three questions (Q1, Q16 and Q13, “Taking medicines more than
once a day is inconvenient”) showed differences ofmore than 1 unit
between the Good-2 and Poor-2 sub-groups; mean scores were
either the same in each sub-group, or the higher values were re-
ported in the Poor-2 group. In the Poor-2 sub-group, a greater than
50% ‘with barrier frequency’ was seen for Q1 and Q16 with the
highest frequency reported for Q1 (77.4%), while in the Good-2 sub-
group, all questions had lower than a 50% ‘with barrier frequency’.
Internal consistency reliability
For the PP population, the ASK-20 demonstrated acceptable
internal consistency reliability, with a Cronbach's alpha of 0.76. The
TBC appeared less reliable, with a Cronbach's alpha of 0.65.
Discriminant validity
In the PP population, the mean ASK-20 total score andmean TBC
discriminated between the good and poor adherence sub-groupsTable 4
Summary of the validity outcomes in which dichotomous responses in criteria by ASK-20
Validity criteria Groupy
Missed dose(s) of any of your medicines in the last 2 weeks Good-1 (n ¼ 205
Poor-1 (n ¼ 85)
Did not take your medicine exactly as directed Good-2 (n ¼ 197
Poor-2 (n ¼ 93)
CI, conﬁdence interval; SD, standard deviation; TBC, total barrier count.
y ‘Good-1’ was deﬁned as the good adherence group that responded ‘No’ to the questio
deﬁned as the poor adherence group who responded ‘Yes’ to the same question; ‘Good-2
there any days that you did not take your medicine exactly as directed in the last 2 weeks
question. Questions were from the treatment adherence questionnaire.
z The mean score and 95% CI have been previously reported.18
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there was no overlap of CI (Table 4). In the regression analysis, all
other factors that might affect adherence were correlated with the
mean ASK-20 total score and TBC in addition to the ‘number of
medicines taken every day’ (Table 5). Statistically signiﬁcant cor-
relations (p < 0.0001) were seen between the mean percentage
prescription rate of ICS adherence and both the mean ASK-20 total
score (r ¼ 0.51) and mean TBC (r ¼ 0.58) showing that the ASK-
20 total score and the TBC decrease when the percentage pre-
scription rate of ICS adherence increases.
For the ICS adherence sub-group, the mean ASK-20 total score
and mean TBC discriminated between groups with high and low
percentage prescription rates of ICS adherence: higher mean ASK-
20 total scores and mean TBC were obtained from those subjects
in the group with a low percentage rate of ICS adherence (Fig. 1).Discussion
In this studywe tested the validity and reliability of the Japanese
version of the ASK-20 using similar statistical models to those used
in studies conducted in the US.11,13total score and total barrier count were analysed (Per Protocol population; n ¼ 290).
ASK-20 total score ASK-20 TBCz
Mean (SD) 95% CI Mean (SD) 95% CI
) 35.7 (8.12) 34.59e36.82 2.7 (2.16) 2.38e2.98
43.5 (8.85) 41.55e45.37 4.9 (2.64) 4.31e5.45
) 35.3 (7.87) 34.23e36.45 2.6 (2.12) 2.32e2.91
43.6 (8.85) 41.75e45.39 4.8 (2.63) 4.29e5.37
n, ‘Have you missed doses of any of your medicines in the last 2 weeks?’; Poor-1 was
’ was deﬁned as the good adherence group that responded ‘No’ to the question, were
?’; Poor-2 was deﬁned as the poor adherence group who responded ‘Yes’ to the same
e “Adherence Starts with Knowledge 20” (ASK-20) questionnaire for
ong term, Allergology International (2016), http://dx.doi.org/10.1016/
Table 5
Association betweenpossible inﬂuencing factors such as age, Asthma Control Test score, number of differentmedicines taken per day; missed dose frequency, dose not taken as
directed and treatment satisfaction on the mean ASK-20 total scores and mean total barrier counts (Per Protocol population; n ¼ 290).
Factor Mean ASK-20 total score Mean TBC
Regression coefﬁcient p-Value Regression coefﬁcient p-Value
Age 0.1526 <0.0001** 0.0298 0.0011*
ACT score 0.2627 0.0141* 0.0918 0.0020*
Number of different medicines taken every day 0.1903 0.2570 0.0222 0.6351
Number of times missed doses of medication (past 2 weeks) 0.8622 <0.0001** 0.2396 <0.0001**
Number of days did NOT take medication exactly as directed (past 2 weeks) 1.0372 <0.0001** 0.2691 <0.0001**
How satisﬁed are you with your current medicines? 4.3010 <0.0001** 0.8985 0.0006**
*p < 0.05; **p < 0.01.
ACT, Asthma Control Test; TBC, total barrier count.
Fig. 1. Plots showing the relationship between a) mean ASK-20 total score or b) mean total barrier count with prescription rate of inhaled corticosteroid adherence (left: 25 to75%,
right: >75 to 125% in each error bar set) (inhaled corticosteroid adherence sub-group; n ¼ 111) ASK, adherence starts with knowledge; CI, conﬁdence interval; ICS, inhaled
corticosteroid; TBC, total barrier count.
R. Atsuta et al. / Allergology International xxx (2016) 1e7 5There were no ceiling effects, but 9 items from ASK-20 showed
ﬂoor effects of which 4 questions (Q3 ‘My use of alcohol gets in the
way of taking my medicines’; Q17 ‘Skipped or stopped taking a
medicine because you didn't think it was working’; Q18 ‘Skipped
or stopped taking a medicine because it made you feel bad’;
and Q19 ‘Skipped, stopped, not reﬁlled, or taken less medicine
because of the cost’) matched those that had shown ﬂoor effects in
the US.13 These ﬁndings suggest that these 4 items are not asPlease cite this article in press as: Atsuta R, et al., Assessing usability of th
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term.
The subjects in our study were under specialist care for their
asthma and were, therefore, more likely to be a high adherence
population compared to those not receiving this care. However, our
results are similar to those obtained from a global validation study
and, therefore, they still demonstrate that this Japanese question-
naire may be reliable.e “Adherence Starts with Knowledge 20” (ASK-20) questionnaire for
ong term, Allergology International (2016), http://dx.doi.org/10.1016/
R. Atsuta et al. / Allergology International xxx (2016) 1e76Acceptable internal consistency reliability was achieved with
the mean ASK-20 total score but not the mean TBC, which is
consistent with published data in a US population.13 Although this
suggests that the ASK-20 scoring is more reliable than TBC, we
agree with Matza et al. that while the ASK-20 score is recom-
mended for use under research conditions, the TBC remains helpful
in clinical settings for improving communication between physi-
cians and patients.13
The 95% CI for the mean ASK-20 total score and mean TBC
successfully discriminated between the poor adherence sub-groups
i.e., those who had missed a dose or had not taken the dose exactly
as directed and good adherence patients i.e., those who had taken
all the medication as directed.
This discrimination and the moderate to high correlation of the
mean ASK-20 total score and mean TBC with most of the factors
affecting medication adherence concurred with US results,11
although it should be noted that age and ACT score were not
examined in either the US or Japanese populations. Signiﬁcant
correlation with percentage ICS adherence was seen with the
mean ASK-20 total score and mean TBC e both discriminated be-
tween the high and low ICS prescription rate groups. Therefore, the
ASK-20 may help to discriminate between different ICS adherence
rates.Study limitations
One of our study centers was a large university hospital in the
metropolitan area of Tokyo. This is perhaps not an ideal environ-
ment in which to monitor subjects because non-specialist physi-
cians examine patients with a variety of conditions within a limited
timeframe. Greater monitoring may have been achieved in primary
care institutions.
An additional limitation was the inﬂuence of Tokyo's sub-
sidisation policy for self-funding patients with bronchial asthma,
which may have underestimated scores for the cost-related item,
Q19. Also, our use of a specialised respiratory centre may have
reduced the effect of treatment adherence barriers compared to if a
non-specialist centre had been used.18
Furthermore, ASK-20 is not the questionnaire only for asthma
patients,13 therefore this includes questions unrelated to asthma.
On the other hand, there are no questions about inhalation tech-
nique or education. These might be limitations in using ASK-20 to
detect asthma speciﬁc adherence barriers.
Finally, only subjects who had taken ICS at a ﬁxed dose for at
least 2 years were enrolled, so a considerable number of poor
adherence subjects might have been excluded thus creating a bias
towards fewer adherence barriers as seen in our study.Future development of the ASK-20 in Japan
Our study represents one step in the ongoing development and
validation of the ASK-20 in Japanese adults and future research is
needed to further validate this instrument. In the future, when
other relevant questionnaires have been translated and validated
for use in Japanese patients, studies comparing the ASK-20 with the
MMAS and MARS would test the validity of the Japanese ASK-20.
This has already been achieved in the US where a strong correla-
tionwas reported between the ASK-20 total score and the following
questionnaires: MMAS (r ¼ 0.61, p < 0.001); Short Form Survey
(SF)-12 (mental health composite score) (r ¼ 0.40, p < 0.001); SF-
12 (physical composite score) (r ¼ 0.19, p < 0.05); and mini
asthma quality of life questionnaire (r ¼ 0.32, p ¼ 0.05).13
ASK-20 is not an asthma speciﬁc questionnaire for asthma pa-
tients. Thereforewewill try continuously to understand the issue ofPlease cite this article in press as: Atsuta R, et al., Assessing usability of th
Japanese adults with bronchial asthma receiving inhaled corticosteroids l
j.alit.2016.09.001adherence and consider effective intervention programwith a view
to develop a new asthma speciﬁc questionnaire.
In conclusion, our results conﬁrm that the Japanese ASK-20 is a
reliable tool for assessing possible medication adherence barriers
and adherence behaviour in Japanese adults with asthma.
Furthermore, our results are comparable with those obtained using
the ASK-20 in the United States.
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